Navigation Links
Endo Pharmaceuticals and BioDelivery Sciences International Sign Licensing Agreement for BEMA Buprenorphine
Date:1/6/2012

CHADDS FORD, Pa., Jan. 6, 2012 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) announced today it has signed a worldwide license and development agreement with U.S.-based BioDelivery Sciences International (Nasdaq: BDSI) for BEMA Buprenorphine.

BEMA Buprenorphine is a transmucosal form of buprenorphine, a partial mu-opiate receptor agonist, which incorporates a bioerodible mucoadhesive (BEMA) technology. BEMA Buprenorphine is currently in phase III trials for the treatment of moderate to severe chronic pain.  

Financial terms of the agreement include an upfront payment of $30 million to BioDelivery Sciences International, royalties of net sales, and up to approximately $150 million in milestones contingent upon achievement of pre-defined, late state clinical and regulatory events and achievement of certain sales targets.

"Endo is committed to serving as an integrated solutions provider for the development and commercialization of products focused on the management of pain," said Dave Holveck, president and chief executive officer of Endo Pharmaceuticals. "The addition of BEMA Buprenorphine will broaden Endo's portfolio of pain therapeutics, allowing us to offer an integrated suite of products that currently include Opana ER, Voltaren Gel and Lidoderm, as well as a broad range of generic pain products. We look forward to working closely with BDSI on the development of this important asset." 

About Endo
Endo Pharmaceuticals is a U.S.-based, specialty healthcare solutions company with a diversified business model, operating in three key business segments – branded pharmaceuticals, generics and devices and services.  We deliver an innovative suite of complementary products and services to meet the needs of patients in areas such as pain management, pelvic health, urology, endocrinology and oncology. For more information about Endo Pharmaceuticals, and its wholly owned subsidiaries American Medical Systems and Qualitest Pharmaceuticals, as well as its affilate HealthTronics, Inc., please visit http://www.endo.com/.

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements.  Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption "Risk Factors" in our Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein, could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in our Annual Report on Form 10-K. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause our actual results to differ materially from expected and historical results. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.


'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioDelivery Sciences Announces Worldwide License and Development Agreement with Endo Pharmaceuticals for BEMA Buprenorphine
2. Savient Pharmaceuticals to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference
3. Acella Pharmaceuticals, LLC Announces Its Acquisition of the PRENATE® Family of Trademarks and Associated Intellectual Property
4. Syndax Pharmaceuticals Signs Agreement with Ventana Medical Systems, Inc. to Develop Companion Diagnostic Test for Entinostat
5. Ampio Pharmaceuticals Schedules Webcast to Update Shareholders
6. Arena Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
7. Inovio Pharmaceuticals to Present at Biotech Showcase Investor Conference
8. MDA Awards $1 Million to Tivorsan Pharmaceuticals for Accelerating Pivotal Pre-Clinical Work on TVN-102 as a Potential Muscular Dystrophy Treatment
9. Lotus Pharmaceuticals Announces Business Reorganization and Provides Updates on the Beijing Headquarters Building
10. Lexicon Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
11. Omthera Pharmaceuticals, Inc. to Present at the 30th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... , February 22, 2017 Arthroscopy Devices Market Report, published by ... 2015 and is projected to reach $5,334 million by 2022, growing at a CAGR ... the total market in 2015. Continue Reading ... ... ...
(Date:2/22/2017)...  Known for selling everyday household products commonly ... prominent California urologist Dr. ... about the British conglomerate that makes those products – ... steal her late husband,s invention, business plans, and other ... Gilbert until his violent death in 2013, filed suit ...
(Date:2/22/2017)... , February 22, 2017 A research ... North America and the continuously changing landscape of ... in 2016 in the North America , a ... to increase to $21.6 billion by the year 2021 representing a ... the United States and Canada ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... ... a new healthcare contact center in Georgia, PENETRON Specialty Products (PSP) provided the ... largest healthcare systems recently invested $51 million to purchase and renovate the 185,000 ...
(Date:2/22/2017)... MD (PRWEB) , ... February 22, 2017 , ... ... Direct secure messaging services to the largest network of hospitals, health information ... the National Coordinator for Health Information Technology (ONC-HIT) 2015 Edition Health IT Module ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... with chronic conditions reported skipping doses or not filling a prescription because they ... under-insured, rates of cost-related problems getting medications were 30-60%*. At the ...
(Date:2/22/2017)... Singapore (PRWEB) , ... February 22, 2017 , ... Using ... medical leads utilizing a simple online checklist. Over a period of just 24 months, ... the assistance of an online checklist called T.A.D. , “The internet is not getting ...
(Date:2/22/2017)... ... February 22, 2017 , ... Bellus Medical, a leader in ... the delivery of Platelet Rich Plasma (PRP). PRP systems are used by physicians ... tissue synthesis and provide a faster and more efficient healing process. There are ...
Breaking Medicine News(10 mins):